CSIMarket Company Name, Ticker, Suppliers, else..
 
Immunogen inc   (IMGN)
Other Ticker:  
 
 
Price: $31.2300 $0.00 0.000%
Day's High: $31.25 Week Perf: 6.59 %
Day's Low: $ 31.22 30 Day Perf: 4.94 %
Volume (M): 48,607 52 Wk High: $ 31.25
Volume (M$): $ 1,517,990 52 Wk Avg: $22.16
Open: $31.24 52 Wk Low: $12.43



 Market Capitalization (Millions $) 8,981
 Shares Outstanding (Millions) 288
 Employees 200
 Revenues (TTM) (Millions $) 288
 Net Income (TTM) (Millions $) -74
 Cash Flow (TTM) (Millions $) 296
 Capital Exp. (TTM) (Millions $) 2

Immunogen Inc
Immunogen Inc. is a biotechnology company that specializes in the development of targeted cancer therapies. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.

Immunogen's core technology is its Antibody Drug Conjugate (ADC) technology, which involves combining potent cancer cell-killing agents called cytotoxic agents with cancer-targeting antibodies. The resulting ADCs are designed to selectively bind to cancer cells, delivering the cytotoxic agents directly to the cancer cells and minimizing damage to healthy cells. This targeted approach aims to improve the efficacy and safety of cancer treatments.

Immunogen has a long history of developing ADCs and its technology platform has been used to develop several clinical-stage products, including mirvetuximab soravtansine, IMGN779, IMGN632, and IMGN15 Mirvetuximab soravtansine is a promising product that targets folate receptor alpha (FRe), which is found on the surface of various types of cancer cells, including ovarian cancer. The drug has demonstrated clinical activity in patients with FRe-positive ovarian cancer and is currently in Phase 3 clinical trials.

In addition to its internal pipeline, Immunogen partners with other companies to develop ADCs using its technology. Some of its notable partnerships include collaborations with Roche, Sanofi, and Takeda.

Immunogen has a strong intellectual property portfolio, with numerous patents covering its ADC technology and processes. The company's technology and products have been recognized with numerous awards and accolades, including the Galien Foundation's Best Biotechnology Product award and the Boston Business Journal's Best Places to Work award.

Overall, Immunogen Inc. is a leader in the development of targeted cancer therapies, with a strong focus on ADCs. Its technology platform and extensive pipeline make it a promising company in the biotechnology industry.


   Company Address: 830 Winter Street Waltham 2451 MA
   Company Phone Number: 895-0600   Stock Exchange / Ticker: NASDAQ IMGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Immunogen Inc

Immunogen Inc Flourishes with Astounding Financial Performance, Achieving Profitability and Revenue Growth of 637.724%



Immunogen Inc, a leading company in the Major Pharmaceutical Preparations sector, has demonstrated impressive financial results in its most recent fiscal period. The company's revenue saw a significant increase of 637.724% year-on-year, reaching $113.43 million. Alongside this remarkable revenue improvement, Immunogen Inc achieved positive earnings per share (EPS) at $0.10. This article will outline the key facts and interpret the implications of these financial results.
Revenue Growth Outpacing Sector Peers:
Immunogen Inc has clearly surpassed its sector peers in terms of top-line growth. While the Major Pharmaceutical Preparations sector reported a revenue improvement of 1.30% during the same period, Immunogen Inc achieved an outstanding growth rate of 637.724%. This indicates that the company's products and services have gained significant market demand, enabling them to outperform competitors in terms of generating revenue.
Immunogen Inc

Immunogen Inc Reports Exceptional Revenue Growth of 487.156% in Q2 2023, Surpassing Pharmaceutical Industry Trends

As a stock market journalist, I have been closely following the financial results of Immunogen Inc for the fiscal second quarter of 2023. It is clear from these results that Immunogen Inc has made significant improvements compared to the previous year.
One notable highlight is the decrease in loss per share, which went from $-0.24 per share a year ago to $-0.02 per share in the current quarter. This represents a substantial improvement in their financial performance. Additionally, the EPS improved from $-0.16 per share in the previous reporting season, indicating positive growth.
Immunogen Inc

Failed to break-even regardless of surge in revenue, in the fiscal first quarter of 2023

Dear Investors,
In recent news, Immunogen Inc. has reported a surge in revenue of 30.965% to $49.87 million from the same reporting season a year before. Though this may seem like a positive development, the company also announced that its deficit has expanded at $-0.16 per share in the January to March 31, 2023 period. This is higher than the previous reporting season, where IMGN realized revenue of $41.17 million, but had a deficit of $-0.19 per share.
Looking at the fiscal first quarter of 2023, Immunogen Inc. recorded a net deficit of $-41.014 million, which is larger than the $-24.145 million a year ago. While this may seem like troubling news at first glance, it's important to look beyond the numbers to make informed decisions.






Immunogen Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com